Role of angiotensin receptor-neprilysin inhibitor in diabetic complications  

作　　者：Ying Liu Cun-Yu Lu Yi Zheng Yu-Min Zhang Ling-Ling Qian Ku-Lin Li Gary Tse Ru-Xing Wang Tong Liu 

机构地区：[1]Department of Cardiology,Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease,Tianjin Institute of Cardiology,Second Hospital of Tianjin Medical University,Tianjin 300211,China [2]Department of Cardiology,Xuzhou No.1 Peoples Hospital,Xuzhou 221005,Jiangsu Province,China [3]Department of Cardiology,Wuxi 9^(th)People’s Hospital Affiliated to Soochow University,Wuxi 214062,Jiangsu Province,China [4]Department of Cardiology,Wuxi People’s Hospital Affiliated to Nanjing Medical University,Wuxi 214023,Jiangsu Province,China [5]School of Nursing and Health Studies,Metropolitan University,Hong Kong 999077,China [6]Kent and Medway Medical School,Kent CT27NT,Canterbury,United Kingdom

出　　处：《World Journal of Diabetes》2024年第5期867-875,共9页世界糖尿病杂志（英文版）（电子版）

基　　金：Supported by Tianjin Key Medical Discipline(Specialty)Construction Project,No.TJYXZDXK-029A;the National Natural Science Foundation of China,No.82370342.

摘　　要：Diabetes mellitus is a prevalent disorder with multi-system manifestations,causing a significant burden in terms of disability and deaths globally.Angio-tensin receptor-neprilysin inhibitor(ARNI)belongs to a class of medications for treating heart failure,with the benefits of reducing hospitalization rates and mortality.This review mainly focuses on the clinical and basic investigations related to ARNI and diabetic complications,discussing possible physiological and molecular mechanisms,with insights for future applications.

关 键 词：Angiotensin receptor-neprilysin inhibitor Diabetic mellitus COMPLICATION 

分 类 号：R587.2[医药卫生—内分泌] R57[医药卫生—内科学]